Lund, Sweden, November 15 2023
This is a translation of the Swedish press release published 2023-11-15
Market preparations for launch in the U.S. continue with a new exclusive collaboration with Stanford, enhanced protection for Neola® through trademark registration in the U.S. and new strong results from a large clinical study on 100 newborn babies – Neola Medical’s CEO tells more in the autumn 2023 investor letter.
In this autumn’s investor letter, CEO Hanna Sjöström tells more about the visit to the jENS conference in Rome, Italy, where the Irish research group from the INFANT Center presented the final results of the independent NIOMI clinical study from University Collage Cork in Irland. In addition, she tells us more about the continued market preparation work for the launch of Neola® in the U.S., which is gaining momentum through a new exclusive collaboration program with Stanford’s experts as well as enhanced trademark protection in the U.S.
Read the investor letter here (in English): Neola Medical Investor Letter Autumn 2023
Read the entire press release, including the investor letter, here (in Swedish): PM Neola Medical Investerarbrev höst 2023
For further information, contact:
Hanna Sjöström, CEO Neola Medical, phone: +46 (0)760-10 71 16, e-mail: email@example.com
Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants’ lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.